Double Burn Mix 25 mg ZPHC: Dual-Pathway Fat-Loss Peptide Research Overview
Double Burn Mix by ZPHC is a lyophilised research peptide formulation combining two hGH-derived fragments — AOD 9604 and FRAG 176-191 — in a 1:1 ratio per vial (2.5 mg each, 5 mg total per vial, 5 vials per kit, 25 mg total). It is supplied strictly for laboratory research purposes and is not approved for human consumption, therapeutic use, or fat-loss treatment.
Product Composition and Reconstitution
Each vial contains AOD 9604 2.5 mg + FRAG 176-191 2.5 mg as a lyophilised powder. Reconstitution with 1 ml bacteriostatic water yields a concentration of 5 mg/ml (2.5 mg/ml of each fragment). The solution should be swirled gently—not shaken—to avoid foaming and peptide degradation. Following reconstitution, storage at 2–8 °C is recommended; the lyophilised powder ships safely at ambient temperature.
What the Research Actually Shows
AOD 9604 is a synthetic analogue of the hGH 176–191 fragment with an added N-terminal tyrosine for stability. Its most rigorous clinical test—a Phase 2b trial (n=536, 24 weeks)—failed to achieve statistical significance for weight loss at any dose, and development was terminated in 2007 . A smaller 12-week trial reported a 2.6 kg loss versus 0.8 kg on placebo, but this result was not replicated in the larger pivotal study .
FRAG 176-191 (the unmodified fragment) has no controlled human trials for fat loss. All clinical data belongs to its modified cousin, AOD 9604 . Preclinical rodent studies suggest the fragment may carry anti-lipogenic activity, but evidence for meaningful lipolysis in humans is absent.
The combination of these two compounds is not supported by published research. No study has examined AOD 9604 + FRAG 176-191 together. Because they share the same core sequence and proposed mechanism—acting through an unidentified pathway without GH receptor activation—running both is widely considered redundant rather than synergistic . Community consensus on both compounds individually is overwhelmingly “zero results” .
Quality Control and Authenticity Claims
ZPHC states that Double Burn Mix is manufactured to ≥99% purity by HPLC with endotoxin levels <0.03 EU/mg. Each box carries a scratch-code for authenticity verification. These are manufacturer-reported specifications; independent third-party verification is not documented in available sources. Note that Double Burn Mix was among products seized by Paraguayan regulatory authorities (Dinavisa) in 2026 for lacking health registration, with the agency warning that such products carry no guarantees of quality, safety, efficacy, or traceability .
Research Dosing (Community-Derived, Not Clinical)
The dosing referenced in your product information—250–500 µg subcutaneously once or twice daily, 30 minutes pre-cardio, 4–6 week course—aligns with community-reported protocols for hGH fragments, not with validated clinical regimens . AOD 9604 clinical trials used oral doses up to 1 mg daily; no injectable human dosing has been established as safe or effective.
Important Limitations for Researchers
-
Not FDA-approved for any indication; sold as a research chemical only
-
Banned by WADA at all times (S2 category)
-
No human safety data exists for the AOD 9604 + FRAG 176-191 combination
-
Reconstituted AOD 9604 has been reported to gel or clump in community settings, complicating consistent dosing
For Laboratory Research Use Only
This product is supplied for in vitro and preclinical research applications only. It is not intended for human or veterinary use, diagnostic purposes, or therapeutic application. Researchers should verify batch-specific certificates of analysis and comply with all applicable institutional and regulatory requirements.
Verify at: https://zphc.com



